Compare Mesoblast Limited (MESO) vs Progressive Corp (PGR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Progressive Corp — how do they compare? Mesoblast Limited trades at $14.29 (market cap $1.75B), while Progressive Corp trades at $217.43 (market cap $126.95B). The key difference: Progressive Corp is far larger — about 72.5× Mesoblast Limited's market cap, and Progressive Corp pays a 0.18% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Progressive Corp for 81 Days on average.
| MESO | PGR | |
|---|---|---|
Market Cap | $1.75B | $126.95B |
Volume | 239,027 | 2,749,438 |
Sector | Health | Financials |
52-Week High | $20.96 | $240.40 |
52-Week Low | $13.19 | $190.40 |
Typical Hold Time | 15 Days | 81 Days |
Enterprise Value | $1.83B | $135.16B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.75, down 1.36% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $102.14 million in 2025, though revenue grew to $120 million in 2026. Recent milestones include FDA approval for a new potency assay and completion of a Phase 3 trial for chronic low back pain, signaling progress in its commercial pipeline.
The outlook is mixed; analyst consensus leans buy (45% buy ratings), but profitability remains a challenge with negative margins. Key risks include high cash burn and competitive pressures, while catalysts hinge on successful commercialization of RYONCIL and upcoming trial results. The stock presents a high-risk, high-reward opportunity in the biotech sector.
PGR trades at $218.73, up 2.15% on the day, with a bullish technical signal and strong fundamentals. Revenue has grown from $49.6B in 2022 to $87.6B in 2025, with net income reaching $11.3B. The stock is supported by a consensus price target of $222.23 and positive analyst sentiment, though RSI levels suggest some near-term overbought conditions.
The outlook for PGR is positive, driven by consistent earnings beats and robust profitability metrics like a 34.94% ROE. Risks include competitive pressures in personal auto insurance and potential market volatility. The stock offers a solid investment opportunity with upside to the price target, but investors should monitor underwriting discipline amid industry competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →
